Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects

References

• Australian Drug Evaluation Committee (ADEC) 258th meeting resolutions. 6 June 2008. [Internet] Australian Government Department of Health, Therapeutic Goods Administration, Resolution 9188; [cited 2016 May 29]. Available from: https://www.tga.gov.au/committee-meeting-info/adec-258th-meeting-resolutions-6-june-2008.
   Google Scholar
• F.D.A. Drug Product List. February 2008. [Internet]. U.S. Department of Health and Human Service, U.S. Food and Drugs Administration; [cited 2016 May 29]. Available from: http://www.fda.gov/drugs/informationondrugs/ucm086232.htm.
   Google Scholar
• Pristiq Product Information. 2014. [Internet] Pfizer Australia Pty Ltd. West Ryde NSW; [cited 2016 May 29]. Available from: http://www.pfizer.com.au/browse-products.
   Google Scholar
• PBAC Public Summary Document – Desvenlafaxine succinate. Nov 2008. [Internet] The Pharmaceutical Benefits Scheme, Australian Government Department of Health; [cited 2016 May 29]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-desvenlafaxine-nov08.
   Google Scholar
• Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14:144–154.
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677–688.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013;13:94.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663–1672.
   PubMed Web of Science ®Google Scholar
• Maity N, Ghosal MK, Gupta A, et al. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014;46:433–437.
   PubMed Web of Science ®Google Scholar
• Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014;7:339–351.
   PubMed Web of Science ®Google Scholar
• Johnson ED, Carroll DG. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharm Pract (Granada). 2011;9:117–121.
   PubMedGoogle Scholar
• Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20:480–490.
   PubMed Web of Science ®Google Scholar
• Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435–443.
   PubMedGoogle Scholar
• Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol. 2008;64:483–487.
   PubMed Web of Science ®Google Scholar
• Behrle JA, Nichols AI, McGrory SB, et al. An open-label, randomized, single dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Clin Pharmacol Ther. 2005;77:P82.
   Google Scholar
• DeMaio W, Kane C, Nichols A, et al. Metabolism studies of desvenlafaxine. J Bioequiv Availab. 2011;3:151–160.
   Google Scholar
• Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31:155–167.
   PubMed Web of Science ®Google Scholar
• Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64:192–197.
   PubMed Web of Science ®Google Scholar
• Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96:369–374.
   PubMed Web of Science ®Google Scholar
• Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009;67:572–576.
   PubMed Web of Science ®Google Scholar
• Kelly C, Dhaun N Laing W, at al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol. 2004;42:67–71.
   PubMed Web of Science ®Google Scholar
• Christoph M, Ebner B, Stolte D, et al. Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine. Eur Neuropsychopharmacol. 2010;20:594–597.
   PubMed Web of Science ®Google Scholar
• Richards LS, Behrle JA, Nichols RJ, et al. An ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects [abstract]. Clin Pharmacol Ther. 2005;77:P84, PII-130.
   Web of Science ®Google Scholar
• Kumar VVP, Isbister GK, Duffull SB. The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdose. Br J Clin Pharmacol. 2011;72:125–132.
   PubMed Web of Science ®Google Scholar
• Forrester MB, Villarreal CL. Comparison of desvenlafaxine and venlafaxine ingestions reported to Texas Poison Centers. J Pharm Technol. 2011;27:35–40.
   Google Scholar
• Dunkley EJ, Isbister GK Sibbritt D, at al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–642.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76:48–57.
   PubMed Web of Science ®Google Scholar
• Chan A, Isbister GK Kirkpatrick CMJ, at al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609–615.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–285.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Newby DA Whyte IM, at al. Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor. Pharmacogenomics J. 2014;14:390–394.
   PubMed Web of Science ®Google Scholar
• Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129–133.
   PubMed Web of Science ®Google Scholar
• Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol. 2008;4:18–20.
   PubMedGoogle Scholar
• Hojer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila). 2008;46:336–337.
   PubMed Web of Science ®Google Scholar
• Santos JG, Do Monte FHM, Russi M, et al. Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats. Braz J Med Biol Res. 2002;34:469–472.
   Web of Science ®Google Scholar
• Shams MEE, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493–502.
   PubMed Web of Science ®Google Scholar
• Mazur JE, Doty JD, Krygiel AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy. 2003;23:1668–1672.
   PubMed Web of Science ®Google Scholar
• Parks V, Patat A, Behrle J, et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects. Clin Pharmacol Ther. 2005;77:P28.
   Google Scholar
• Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
   PubMed Web of Science ®Google Scholar